ArticleActa pharmaceutica Sinica. B2025

Targeting SARS-CoV-2 main protease for the discovery of a broad-spectrum COVID-19 inhibitor by intensive multi-tiered validation.

Min Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.